For the Right Perspective & Competitive Insights. Make confident decisions using our benchmarks and analysis.
Download FREE Sample Report
Read the 120-page report with TOC on "Migraine Therapeutics Market Analysis Report by Product (drugs and devices) and Geography (North America, Europe, Asia, and ROW), and the Segment Forecasts,2021-2025". Gain competitive intelligence about market leaders. Track key industry opportunities, trends, and threats. Information on marketing, brand, strategy and market development, sales and supply functions.
More Details: https://www.technavio.com/report/report/migraine-therapeutics-market-industry-analysis
The migraine therapeutics market is driven by the increase in the number of patients suffering from migraines. In addition, the rising advances in migraine therapeutics are anticipated to boost the growth of the migraine therapeutics market.
The overdose of pain-relief medicines can also lead to migraines. The frequent use of some medications can lead to the development of a disabling condition termed medication-overuse headache (MOH). Some of the other reasons that trigger migraine are lack of sleep, hunger, changes in the weather, excessive stimulation of the senses, and stress. Women are considered to be more susceptible to migraines and less responsive to migraine treatment. The fluctuations in estrogen levels affect the cells in the brain. Estrogen creates an electrical phenomenon in women's brains called cortical spreading depression, which is considered to be associated with migraine. The high prevalence of migraines across the world is expected to increase the demand for migraine therapeutics.
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
Enquire Before purchasing
Major Five Migraine Therapeutics Companies:
AbbVie Inc.
AbbVie Inc. operates business through Unified Business. The company provides acute treatment for Migraines with or without Aura in adults, under the brand name UBRELVY.
Amgen Inc.
Amgen Inc. operates business through Unified Business Segment. The company provides treatment for Migraines under the brand name Aimovig.
eNeura Inc.
eNeura Inc. operates business through the Unified segment. The company provides acute and prophylactic treatment of migraine headaches in adolescents (age 12 and older) and adults under the brand name sTMS mini.
GlaxoSmithKline Plc
GlaxoSmithKline Plc operates business through Pharmaceuticals, Consumer Healthcare, and Vaccines. The company provides treatment to Migraine under the brand name Excedrin.
Grunenthal GmbH
Grunenthal GmbH operates business through the Unified segment. The company provides Zolmitriptan under the brand names Zoning and AscoTop for acute treatment of Migraines.
Migraine Therapeutics Market Product Outlook (Revenue, USD billion, 2020-2025)
- Drugs - size and forecast 2020-2025
- Devices - size and forecast 2020-2025
Migraine Therapeutics Market Geography Outlook (Revenue, USD billion, 2020-2025)
- North America - size and forecast 2020-2025
- Europe - size and forecast 2020-2025
- Asia - size and forecast 2020-2025
- ROW - size and forecast 2020-2025
Are you a start-up willing to make it big in the business? Download FREE Sample Report
Related Reports on Health Care Include:
Global Vaccines Market- The vaccine market is segmented by type (prophylactic vaccines and therapeutic vaccines) and geography (North America, Europe, Asia, and ROW).
Download FREE Sample Report
Global ENT Disorder Treatment Market- The ENT disorder treatment market is segmented by indication (rhinitis, sinusitis, otitis media, and tonsillitis) and geography (North America, Europe, Asia, and ROW).
Download FREE Sample Report
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
Report Page: https://www.technavio.com/report/migraine-therapeutics-market-industry-analysis
SOURCE Technavio
Share this article